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Editors’ NotesLocalized Cell Replacement
Two papers in this issue provide insight as to the source and localized regulation of replacement cells that arise in aged or
damaged tissues. In one example, Martin-Villalba and coauthors study the murine central nervous system and reveal
that CD95—primarily considered a component of the apoptotic machinery—can mediate stem cell survival during niche-
localized neurogenesis. The PI3K/mTor signaling cascade appears involved, and ischemia-induced
behavioral impairment can be rescued by CD95-mediated neurogenesis. Meanwhile, in the Drosophila
testis, Matunis and colleagues show that enforced differentiation and subsequent loss of germline
stem cells can be recovered following removal of the Bam differentiation factor from the vicinity of
the hub, or germline stem cell niche. In the absence of the stem cell pool, relatively mature spermato-
gonia dedifferentiate in a Jak/STAT-dependent manner and reoccupy the vacated spaces at the hub.
In both cases, the authors reveal important signaling cascades that mediate the genesis and mainte-
nance of new stem cells and highlight the importance of regionally restricted cues in supporting the
primitive cells.
Signaling In and Out of Pluripotency
Much of the focus on studying the regulation of pluripotency has been centered on the role of transcription factors and epige-
netic mechanisms. In this issue, two studies take a different approach and use differentiation induction protocols to map the
phosphoproteome of hESCs in the pluripotent state. Krijgsveld and coauthors use BMP to promote extraembryonic differen-
tiation over a period of hours, whereas Brill and colleagues use 4 days of retinoic acid exposure to direct cells toward an ecto-
derm fate. Interestingly, there is a strong degree of overlap between the pluripotent phosphoproteomes reported by the two
groups, as discussed in the Preview from Hutchins and Robson. Furthermore, the cell-cycle regulators CDK1/2 were identi-
fied as important players in the maintenance of pluripotency, and this finding is in line with the discussion offered by Robson
and coauthors in their Review. Pluripotent cells exhibit an unusual pattern of cell-cycle progression, and this structure
is common to both ESCs and iPSCs. Regulation of the cell cycle appears important to the maintenance of the pluripotent
state, and the authors review some of the evidence that also implicate the transcription factor Myc in participating in the
process. Similarity between iPSCs and ESCs is also featured in the Brief Report by Gao and colleagues, who show that
a mouse iPSC line that they have derived can generate full-term embryos in a tetrapoloid complementation assay—a stringent
test of pluripotency that iPSCs have not previously met. It will be interesting to see whether the characteristics of this iPSC line,
including its pluripotency networks and phosphoproteome, have features that account for its ability to succeed where other
iPSC lines have not.
Animal Models of Potential Therapies
Last month’s issue featured a research article from the Lock laboratory (5: 31) describing how treatment with anti-CD123
selectively blocks the tumor-forming capacity of human leukemia stem cells in a xenograft assay. Now, Hoey et al. use a
similar approach to block the growth of primary human xenografts in two different solid tumor models. In this case, human-
and mouse-selective anti-DLL4 antibodies interfere with both the grafted tumor cells (by blocking the Notch signaling
cascade) and with host-derived angiogenesis. Both the Lock and Hoey studies also demonstrate that their antibody-medi-
ated effects synergize with existing clinical chemotherapeutic agents in animal models, opening doors to potential new
combination therapies for testing in clinical trials. An important aspect of designing translational trials that builds upon animal
models, as pointed out in the Letter from Jolkkonen and coauthors, is to ensure that the read-outs of preclinical models are
sufficiently rigorous to avoid premature translation to the clinic. In their specific illustration, drawn from an analysis of
published animal models, the choice of specific behavioral tests used to assay the impact of cell-mediated therapy of exper-
imental stroke may increase or decrease the likelihood of observing a functional improvement and, thus, potentially give
a misleading impression of the functional impact of transplanted cells.
Extrinsic Wnt Inhibition Strikes Again
The role of the Wnt/b-catenin cascade in the regulation of hematopoietic stem and progenitor cells continues to be a
contested issue, as outlined in a Review article from Malhotra and Kincade published earlier this year (4: 27). In this issue,
Oostendorp and colleagues combine in vitro and in vivo analyses to reveal that deletion of a soluble
Wnt inhibitor, Secreted frizzled-related protein 1 (Sfrp1), leads to alterations in the pool size of pheno-
typic HSCs at homeostasis, although their function appears intact when required to reconstitute
myeloablated recipients after transplantation. In contrast, serial transplantation to wild-type hosts after
exposure to the SFRP1-deficient environment results in loss of HSC survival and function, consistent
with the findings from Scadden and colleagues (2: 274) who showed that niche-mediated Wnt inhibition
can impair long-term, serial reconstitution potential of HSCs. It remains unclear precisely what targets
and/or mechanisms are responsible for the observed results, but the regulation of cell cycling is likely to
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